title: Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline.
authors.affiliation: From the *Nordic Bioscience, Herlev Hovedgade, Herlev, Denmark; and †Roche Products Ltd, Welwyn Garden City, United Kingdom.
authors.forename: Anne C
authors.initials: AC
authors.lastname: Bay-Jensen
authors.forename: Inger
authors.initials: I
authors.lastname: Byrjalsen
authors.forename: Anne Sofie
authors.initials: AS
authors.lastname: Siebuhr
authors.forename: Claus
authors.initials: C
authors.lastname: Christiansen
authors.forename: Adam
authors.initials: A
authors.lastname: Platt
authors.forename: Morten A
authors.initials: MA
authors.lastname: Karsdal
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood; D003238:Connective Tissue / Q000378:metabolism*; D003663:Decision Trees; D016326:Extracellular Matrix Proteins / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007596:Joints / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D019947:Receptors, Interleukin-6 / Q000276:immunology; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D016326:Extracellular Matrix Proteins; D019947:Receptors, Interleukin-6; C502936:tocilizumab